scorecardresearchNatco Pharma Share Price Live NSE, BSE, Today - Natco Pharma Stock Price
Mintgenie
Asian Paints2,808.45-6.30 (-0.22%)
Axis Bank1,029.505.35 (0.52%)
Bajaj Finance7,107.00217.75 (3.16%)
Bajaj Finserv1,619.6025.35 (1.59%)
Bharti Airtel1,289.3022.10 (1.74%)
HCL Technologies1,450.00-17.65 (-1.20%)
HDFC Bank1,531.3036.70 (2.46%)
Hindustan Unilever2,232.2517.30 (0.78%)
ICICI Bank1,066.4010.95 (1.04%)
ITC424.805.85 (1.40%)
Indusind Bank1,485.8011.85 (0.80%)
Infosys1,411.60-8.95 (-0.63%)
Kotak Mahindra Bank1,790.003.55 (0.20%)
Larsen & Toubro3,519.25-31.70 (-0.89%)
Mahindra & Mahindra2,082.9058.75 (2.90%)
Maruti Suzuki India12,669.35273.05 (2.20%)
NTPC350.90-0.50 (-0.14%)
Nestle India2,437.10-25.65 (-1.04%)
Power Grid Corporation Of India281.701.50 (0.54%)
Reliance Industries2,941.6013.45 (0.46%)
State Bank Of India750.806.00 (0.81%)
Sun Pharmaceutical Industries1,525.007.85 (0.52%)
Tata Consultancy Services3,827.45-36.05 (-0.93%)
Tata Motors963.20-8.20 (-0.84%)
Tata Steel162.102.10 (1.31%)
Tech Mahindra1,193.7513.90 (1.18%)
Titan Company3,563.8037.40 (1.06%)
Ultratech Cement9,399.1011.90 (0.13%)
Wipro452.858.55 (1.92%)

Natco Pharma

BSE: 524816 | NSE: NATCOPHARM | ISIN: INE987B01026 | SECTOR: Biotechnology & Drugs

₹1,001.00 6.50 (0.65%)

19 Apr 2024, 09:59 (IST)

  • Open

    980.45

  • High

    1,004.80

  • Low

    980.45

  • Prev Close

    994.50

  • P/E

    -

  • Median P/E

    -

  • P/B

    -

  • Median P/B

    -

  • Market Cap

    179.29B

  • Volume

    15.80K

  • Vol. (20 day Avg.)

    0

  • PEG

    -

  • Div.Yield

    -

  • Bid

    -

  • Ask

    -
View all metrics

Company Description

  • Biotechnology & Drugs

  • BSE

    524816

  • NSE

    NATCOPHARM

  • ISIN

    INE987B01026

Natco Pharma Limited is an India-based vertically integrated, research and development (R&D)-focused pharmaceutical company. The Company is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The Company deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The Company operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.

Company Officers

  • Venkaiah Nannapaneni

    Chairman of the Board, Managing Director, Executive Director

  • Rajeev Nannapaneni

    Chief Executive Officer, Vice Chairman of the Board, Executive Director

  • S. V. V. N. Appa Rao

    Chief Financial Officer

  • Lingarao Donthineni

    President - Technical Affairs, Executive Director

  • Pavan Bhat

    Executive Vice President - Technical Operations, Executive Director

  • Potluri Prasad

    Executive Vice President - Corporate Engineering Services, Executive Director

  • Rajesh Chebiyam

    Executive Vice President - Crop Health Sciences

  • Ramesh Dandala

    Executive Vice President - Technology Transfer, Intellectual Property Rights and Regulatory Affairs (API)

  • M. Pullam Reddy

    Executive Vice President - R&D

  • Srinivas C. H.

    Senior Vice President - Demand and Supply Planning